• Grail Inc GRAL.OQ reported a quarterly adjusted loss of $3.18​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-51.06. The mean expectation of four analysts for the quarter was for a loss of $3.57 per share. Wall Street expected results to range from $-4.12 to $-3.14 per share.

• Revenue was $35.54 million​; analysts expected $37.57 million.

• Grail Inc's reported EPS for the quarter was a loss of $3.18​.

• The company reported a quarterly loss of $113.99 million.

• Grail Inc shares had fallen by 36.4% this quarter and gained 83.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Grail Inc is $40.50, about 19.3% above its last closing price of $32.69

This summary was machine generated from LSEG data August 12 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)